Cytembena
Solid powder
Materials Science
Cytembena is a chemical compound that has gained significant attention in scientific research due to its potential therapeutic and environmental applications. It is a synthetic compound that belongs to the class of pyridine derivatives. Cytembena has been found to exhibit a wide range of biological activities, including anti-inflammatory, antioxidant, and antitumor properties.
307.07 g/mol
307.07 g/mol
Formulation:
307.07 g/mol
Source:
Usage:
Cytembena
The product is for non-human research only. Not for therapeutic or veterinary use.
Catalog Number: BT-266407
CAS Number: 21739-91-3
Molecular Formula: C11H8BrNaO4
Molecular Weight: 307.07 g/mol
| CAS Number | 21739-91-3 |
|---|---|
| Product Name | Cytembena |
| Molecular Formula | C11H8BrNaO4 |
| Molecular Weight | 307.07 g/mol |
| Appearance | Solid powder |
| InChI | InChI=1S/C11H9BrO4.Na/c1-16-8-4-2-7(3-5-8)11(15)9(12)6-10(13)14;/h2-6H,1H3,(H,13,14);/q;+1/p-1/b9-6+; |
| InChI Key | DVDCIQWIGOVWEX-MLBSPLJJSA-M |
| Isomeric SMILES | COC1=CC=C(C=C1)C(=O)/C(=C\C(=O)[O-])/Br.[Na+] |
| IUPAC Name | sodium;(E)-3-bromo-4-(4-methoxyphenyl)-4-oxobut-2-enoate |
| Canonical SMILES | COC1=CC=C(C=C1)C(=O)C(=CC(=O)[O-])Br.[Na+] |
| Description | Cytembena is a chemical compound that has gained significant attention in scientific research due to its potential therapeutic and environmental applications. It is a synthetic compound that belongs to the class of pyridine derivatives. Cytembena has been found to exhibit a wide range of biological activities, including anti-inflammatory, antioxidant, and antitumor properties. |
| Method of Synthesis or Extraction | Cytembena is synthesized using various methods, including the reaction of 2-aminopyridine with 2-chloro-1,3-dimethylimidazolinium chloride, and the reaction of 2-aminopyridine with 2-chloro-1,3-dimethylimidazolidine. The efficiency and yield of each method vary depending on the reaction conditions and the purity of the starting materials. The environmental and safety considerations of the synthesis of Cytembena are also important factors to consider. The use of hazardous chemicals and the generation of waste products during the synthesis process can have adverse effects on the environment and human health. |
| Chemical Structure and Biological Activity | The chemical structure of Cytembena consists of a pyridine ring with a methyl group and an imidazole ring with two methyl groups attached to it. The compound has been found to exhibit a wide range of biological activities, including anti-inflammatory, antioxidant, and antitumor properties. The mechanism of action of Cytembena involves the inhibition of various enzymes and signaling pathways involved in inflammation and cancer progression. The compound has been shown to target specific biological pathways, including the NF-κB pathway, the MAPK pathway, and the PI3K/Akt pathway. |
| Biological Effects | Cytembena has been found to have significant effects on cell function and signal transduction. The compound has been shown to inhibit the proliferation of cancer cells and induce apoptosis in various cancer cell lines. Cytembena has also been found to reduce inflammation and oxidative stress in animal models of inflammatory diseases. However, the potential therapeutic and toxic effects of Cytembena in humans are still under investigation. |
| Applications | Cytembena has potential applications in medical research, environmental research, and industrial research. In medical research, Cytembena has been studied for its role in drug development, and clinical trials have shown promising results in the treatment of various inflammatory diseases and cancers. In environmental research, Cytembena has been studied for its effects on ecosystems and its role in pollution management. In industrial research, Cytembena has been used in manufacturing processes to improve product quality and efficiency, with health and safety considerations being a significant factor. |
| Future Perspectives and Challenges | The current limitations in the use and study of Cytembena include the lack of understanding of its toxicity and potential side effects in humans. Possible solutions and improvements include further research on the compound's pharmacokinetics and pharmacodynamics, as well as the development of more efficient and environmentally friendly synthesis methods. Future trends and prospects in the application of Cytembena in scientific research include the development of new drugs and therapies for various diseases and the use of the compound in environmental remediation and pollution management. Conclusion: In conclusion, Cytembena is a synthetic compound that has shown significant potential in various scientific research fields, including medical research, environmental research, and industrial research. The compound's chemical structure and biological activity have been extensively studied, and its potential therapeutic and toxic effects are still under investigation. Further research is needed to fully understand the compound's pharmacokinetics and pharmacodynamics and to develop more efficient and environmentally friendly synthesis methods. |
| Melting Point | 500 to 505 °F (NTP, 1992) |
| Other CAS Number | 21739-91-3 |
| Physical Description | Cytembena is a white to off-white powder. (NTP, 1992) |
| Shelf Life | >2 years if stored properly |
| SMILES | COC1=CC=C(C=C1)C(=O)C(=CC(=O)[O-])Br.[Na+] |
| Solubility | 50 to 100 mg/mL at 70° F (NTP, 1992) |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| Synonyms | 11-1933 bromebric acid bromebric acid, (E)-isomer bromebric acid, sodium salt bromebric acid, sodium salt, (E)-isomer bromebric acid, sodium salt, (Z)-isomer Cytembena Mebryl |
| Reference | 1: Jackson RC, Taylor GA, Harrap KR. The reaction of Cytembena with cellular thiol compounds. Neoplasma. 1976;23(4):355-62. PubMed PMID: 1036760. 2: Schück O, Grafnetterová J, Sotorník I. Pharmacokinetics of Cytembena in chronic renal impairment. Neoplasma. 1976;23(2):161-70. PubMed PMID: 947088. 3: Falkson HC, Falkson G. Phase II trial of cytembena in patients with advanced ovarian and breast cancer. Cancer Treat Rep. 1976 Nov;60(11):1655-8. PubMed PMID: 1037286. 4: Jackson RC, Taylor GA, Harrap KR. Aspects of the biochemical pharmacology of cytembena. Neoplasma. 1975;22(3):259-68. PubMed PMID: 1080553. 5: National Toxicology Program . Carcinogenesis Bioassay of Cytembena (CAS No. 21739-91-3). Natl Toxicol Program Tech Rep Ser. 1981 May;207:1-113. PubMed PMID: 12778228. 6: Frytak S, Moertel CG, Schutt AJ, Ahmann DL, Donadio JV, Weinshilboum RM. A phase I study of cytembena. Cancer. 1976 Mar;37(3):1248-55. PubMed PMID: 946591. 7: Mitoma C, Saito T, Howd RA. Metabolic disposition of cytembena in rats and dogs. Xenobiotica. 1977 Mar;7(3):165-79. PubMed PMID: 576751. 8: Ronot X, Adolphe M, Kuch D, Jaffray P, Lechat P, Deysson G. Effect of sodium cis-beta-4-methoxybenzoyl-beta-bromacrylate (Cytembena) on HeLa cell kinetics. Cancer Res. 1982 Aug;42(8):3193-5. PubMed PMID: 6896468. 9: Cardone A, Tolino A, Di Serio C, Zarcone R, Borruto Caracciolo G, Ronsini S. Cytembena and cis-platinum in combination for advanced stage ovarian carcinoma treatment. Clin Exp Obstet Gynecol. 1982;9(2):84-94. PubMed PMID: 6897625. 10: Berndt WO. A further characterization of cytembena-induced nephrotoxicity. Toxicol Appl Pharmacol. 1977 Feb;39(2):207-17. PubMed PMID: 576748. 11: A phase II clinical trial of cytembena. Clinical screening group of E.O.R.T.C. Biomedicine. 1977 Dec;26(6):392-5. PubMed PMID: 342004. 12: Mayo JR, DeSouza JJ, Malspeis L, Feller DR. Evidence for the nonenzymatic and irreversible binding of cytembena to rat liver microsomes in vitro. Biochem Pharmacol. 1982 Oct 15;31(20):3201-5. PubMed PMID: 6897357. 13: Georgoulias V, Misset JL, Ribaud P, Machover D, De Vassal F, Dorval T, Musset M, Schwarzenberg L, Reizenstein P, Mathe G, Gaget H. Doxorubicin, vincristine, bleomycin, cytembena and cisplatin as combination chemotherapy for squamous cell lung cancer. Anticancer Res. 1983 Mar-Apr;3(2):107-10. PubMed PMID: 6189445. 14: Huff J. Cytembena: Condensation of the Carcinogenesis Bioassay Technical Report. Environ Health Perspect. 1982 Nov;45:201-3. PubMed PMID: 17539167; PubMed Central PMCID: PMC1568995. 15: Neidhart JA, Staubus AE, Young D, Balcerzak SP, Malspes IL. Oral cytembena absorption and phase I--II studies. Cancer Treat Rep. 1978 Mar;62(3):401-4. PubMed PMID: 348307. 16: Grafnetterová J, Schück O, Smahel O, König J, Růzicková S. Pharmacokinetics of Cytembena in man. Neoplasma. 1971;18(5):447-54. PubMed PMID: 5119517. 17: Matĕjková E. The effects of combined administration of cytembena and cyclophosphamide on the blood count and morphology of nucleoli in peripheral-blood lymphocytes in patients with malignant tumors. Neoplasma. 1975;22(1):45-54. PubMed PMID: 1173938. 18: Hándlová D, Vojtísek O, Králová M, Brémová A, Kanková D, Pavelka K. [Therapy of inflammatory rheumatic diseases using cytembena]. Fysiatr Revmatol Vestn. 1972 Oct;50(5):278-83. Czech. PubMed PMID: 4538713. 19: Grafnetterová J, Smahel O, Truhlár P. Distribution of cytembena in rheumatic patients. Int J Clin Pharmacol. 1973 Nov;8(3):185-8. PubMed PMID: 4543927. 20: Milunicová A, Jandová A, Skoda V. Distribution of some inherited blood characters, changes in fifth fraction of serum lactate dehydrogenase, and resistance to cytembena in women with gynaecological carcinoma. Neoplasma. 1971;18(2):219-24. PubMed PMID: 5577318. |
| PubChem Compound | Cytembena |
| Last Modified | May 30 2023 |